Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCUS 
Arcus Biosciences Inc (RCUS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: RCUS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $30.2
1 Year Target Price $30.2
| 8 | Strong Buy |
| 3 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.14% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.44B USD | Price to earnings Ratio - | 1Y Target Price 30.2 |
Price to earnings Ratio - | 1Y Target Price 30.2 | ||
Volume (30-day avg) 13 | Beta 0.78 | 52 Weeks Range 6.50 - 22.11 | Updated Date 11/5/2025 |
52 Weeks Range 6.50 - 22.11 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-10-28 | When - | Estimate -1.28 | Actual -1.27 |
Profitability
Profit Margin -142.08% | Operating Margin (TTM) -546.15% |
Management Effectiveness
Return on Assets (TTM) -21.06% | Return on Equity (TTM) -68.13% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 620982149 | Price to Sales(TTM) 10.18 |
Enterprise Value 620982149 | Price to Sales(TTM) 10.18 | ||
Enterprise Value to Revenue 2.37 | Enterprise Value to EBITDA 3.96 | Shares Outstanding 123728536 | Shares Floating 61535198 |
Shares Outstanding 123728536 | Shares Floating 61535198 | ||
Percent Insiders 27.06 | Percent Institutions 52.81 |
Upturn AI SWOT
Arcus Biosciences Inc
Company Overview
History and Background
Arcus Biosciences Inc. was founded in 2015. It is a clinical-stage biopharmaceutical company focused on creating differentiated cancer therapies.
Core Business Areas
- Small Molecule Programs: Develops small molecule therapies targeting cancer cell growth and survival mechanisms.
- Antibody Programs: Creates antibody-based therapies designed to enhance the body's immune response against cancer.
Leadership and Structure
Key leaders include Terry Rosen, PhD, CEO, and Jennifer Doudna, PhD, a scientific advisor. The company has a structured research and development team.
Top Products and Market Share
Key Offerings
- Domvanalimab: An anti-TIGIT antibody in Phase 3 trials for non-small cell lung cancer (NSCLC) and other cancers. Competitors: Roche's tiragolumab.
- Etrumadenant: An A2a/b adenosine receptor antagonist in Phase 2/3 trials. Competitors: AstraZeneca.
- Quemliclustat: A small molecule CD73 inhibitor. Competitors: Several companies developing CD73 inhibitors.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advances in cancer diagnostics and treatment.
Positioning
Arcus focuses on novel immuno-oncology approaches. Competitive advantage lies in its diversified pipeline and partnerships.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Arcus targets specific segments within this market.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of novel immuno-oncology agents
- Strong partnerships with Gilead
- Experienced management team
- Promising clinical trial results
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition from established pharmaceutical companies
- Relatively early stage of development
Opportunities
- Potential for regulatory approvals of key pipeline candidates
- Expansion of partnerships and collaborations
- Advancements in cancer diagnostics and personalized medicine
- Untapped indications for existing therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immuno-oncology therapies
- Pricing pressures
Competitors and Market Share
Key Competitors
- GILD
- BMY
- MRK
- AZN
- ROSY
Competitive Landscape
Arcus faces competition from established pharmaceutical companies with deeper pockets and larger pipelines. Arcus has a strong partnership with Gilead.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in the pipeline and partnerships.
Future Projections: Future growth depends on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing key pipeline candidates into late-stage clinical trials and expanding partnerships.
Summary
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on immuno-oncology with a diversified pipeline and strong partnership with Gilead. Its success hinges on clinical trial outcomes and regulatory approvals of its key candidates. The high cash burn rate and competition from larger companies pose risks. Pipeline advancements and partnership expansions offer growth opportunities.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arcus Biosciences Inc. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcus Biosciences Inc
Exchange NYSE | Headquaters Hayward, CA, United States | ||
IPO Launch date 2018-03-15 | Co-Founder, Chairman & CEO Dr. Terry J. Rosen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 627 | Website https://www.arcusbio.com |
Full time employees 627 | Website https://www.arcusbio.com | ||
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.